Botulinum toxin in clinical practice
- PMID: 15201348
- PMCID: PMC1739107
- DOI: 10.1136/jnnp.2003.034702
Botulinum toxin in clinical practice
Abstract
Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.
Similar articles
-
Botulinum toxin in movement disorders.Semin Neurol. 2007 Apr;27(2):183-94. doi: 10.1055/s-2007-971171. Semin Neurol. 2007. PMID: 17390263 Review.
-
Clinical comparison of botulinum toxin in motor and autonomic disorders: Similarities and differences.Toxicon. 2015 Dec 1;107(Pt A):68-71. doi: 10.1016/j.toxicon.2015.07.001. Epub 2015 Jul 3. Toxicon. 2015. PMID: 26143736
-
Other noncosmetic uses of BOTOX.Dis Mon. 2002 May;48(5):357-66. doi: 10.1053/mda.2001.25136. Dis Mon. 2002. PMID: 12195265 Review.
-
Treatment of gastrointestinal sphincters spasms with botulinum toxin A.Toxins (Basel). 2015 May 29;7(6):1882-916. doi: 10.3390/toxins7061882. Toxins (Basel). 2015. PMID: 26035487 Free PMC article. Review.
-
[Indications and management of botulinum toxin].Rev Neurol. 1999 Jul 16-31;29(2):157-62. Rev Neurol. 1999. PMID: 10528331 Review. Spanish.
Cited by
-
Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.J Med Chem. 2020 Oct 8;63(19):11100-11120. doi: 10.1021/acs.jmedchem.0c01006. Epub 2020 Sep 18. J Med Chem. 2020. PMID: 32886509 Free PMC article.
-
Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A.J Physiol. 2013 Feb 15;591(4):1017-29. doi: 10.1113/jphysiol.2012.239178. Epub 2012 Oct 8. J Physiol. 2013. PMID: 23045348 Free PMC article. Clinical Trial.
-
Picolinic acids as β-exosite inhibitors of botulinum neurotoxin A light chain.Chem Commun (Camb). 2016 Oct 13;52(84):12521-12524. doi: 10.1039/c6cc06749b. Chem Commun (Camb). 2016. PMID: 27722252 Free PMC article.
-
[Intravesical therapy for overactive bladder].Urologe A. 2006 Feb;45(2):167-8, 170-3. doi: 10.1007/s00120-006-1000-3. Urologe A. 2006. PMID: 16437248 Clinical Trial. German.
-
Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain.PLoS Pathog. 2007 Sep 7;3(9):1191-4. doi: 10.1371/journal.ppat.0030113. PLoS Pathog. 2007. PMID: 17907800 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical